Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.
Resistance to imatinib mesylate (also known as Gleevec, Glivec, and STI571) often becomes a barrier to the treatment of chronic myelogenous leukemia (CML). In order to identify markers of the action of imatinib mesylate, we used a mass spectrometry approach to compare protein expression profiles in human leukemia cells (K562) and in imatinib mesylate-resistant human leukemia cells (K562-R) in the presence and absence of imatinib mesylate. We identified 118 differentially regulated proteins in these two leukemia cell-lines, with and without a 1 microM imatinib mesylate challenge. Nine proteins of unknown function were discovered. This is the first comprehensive report regarding differential protein expression in imatinib mesylate-treated CML cells.
Park
Jungeun
J
Division of Molecular Genomic Medicine and #Cancer Research Institute, College of Medicine, Seoul National University, Yongon-Dong, Seoul 110-799, Korea.
Kim
Sangmi
S
Oh
Jong K
JK
Kim
Jin Y
JY
Yoon
Sung Soo
SS
Lee
Dongsoon
D
Kim
Youngsoo
Y
D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D019008:Drug Resistance, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D013058:Mass Spectrometry / Q000379:methods; D010879:Piperazines / Q000494:pharmacology*; D040901:Proteomics / Q000379:methods; D011743:Pyrimidines / Q000494:pharmacology*; D011993:Recombinant Fusion Proteins / Q000737:chemistry
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; D000068877:Imatinib Mesylate